Slide 1: Second Quarter 2026 Financial Results
FIRST QUARTER Second 2025Quarter 2026 FINANCIAL Financial Results RESULTS August 3, 2026 Presentation intended for the investment community ©2025 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated
Slide 2: Agenda
Agenda Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Duncan McKechnie, Executive Vice President and Chief Commercial Officer Financial Results Charlie Wagne
Slide 3: Safe harbor statement & non-GAAP financial measures
Safe harbor statement & non-GAAP financial measures This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the information provided regarding future financial and operating performance, including the st
Slide 4: Strong Q2:26 performance across the board
Strong Q2:26 performance across the board Commercial Clinical Regulatory • Total revenue +12% Y/Y • Completed enrollment: • Pove: BLA for IgAN accepted in VX-407 AGLOW Ph2 in ADPKD U.S. • Strong growth across all • products & regions • On track to enroll by YE: • November 30 PDUFA date • Meaningful
Slide 5: Crinetics Pharma acquisition to add 5th disease area pillar
Crinetics Pharma acquisition to add 5th disease area pillar: rare endocrine diseases Enhances VRTX revenue growth and long-term earnings profile Cystic fibrosis Heme Pain Renal Endocrine • ALYFTREK • CASGEVY SCD • JOURNAVX • Pove IgAN • PALSONIFY • TRIKAFTA (acute) • Pove pMN • Atumelnant • CASGEVY
Slide 6: CF: Extending leadership and driving sustained growth
CF: Extending leadership and driving sustained growth ALYFTREK & TRIKAFTA now reach ~95% of all people with CF • Best CFTR protein function, as measured by sweat chloride, plus once-daily dosing • Expect majority of patients to switch to ALYFTREK from TRIKAFTA over time ALYFTREK • New data at ECFS d
Slide 7: Povetacicept: BLA under review for Accelerated Approval in IgAN
Povetacicept: BLA under review for Accelerated Approval in IgAN, PDUFA date Nov. 30 Phase 3 Interim Analysis cemented pove’s potential as best-in-class in IgAN Specifically engineered to RAINIER IA data support Differentiated monthly dosing & achieve improved… potential best-in-class profile patient
Slide 8: Povetacicept: Pipeline-in-a-product potential with promising ongoing clinical trials
Povetacicept: Pipeline-in-a-product potential with promising ongoing clinical trials delivering on key milestones PATIENTS1 CURRENT PHASE 2026 ACHIEVEMENTS AND MILESTONES PDUFA: November 30, 2026 Povetacicept – IgAN Phase 3 trial Completed regulatory submission in ~330K enrollment the Kingdom of
Slide 9: AMKD: Upcoming milestones for inaxaplin in APOL1-mediated kidney disease
AMKD: Upcoming milestones for inaxaplin in APOL1-mediated kidney disease First potential targeted therapy for patients with AMKD • IA data expected early 2027 (after 48 weeks of treatment); if positive, file for potential accelerated approval in the U.S. AMKD Patients with 2 APOL1 • On track to comp
Slide 10: T1D: Zimislecel Ph 1/2/3 has resumed dosing patients
T1D: Zimislecel Ph 1/2/3 has resumed dosing patients + IND cleared for VX-017 VX-017 (blood type O, or universal donor) will initiate a Phase 1/2 trial in the near term Insulin-producing islet cells FDA cleared IND for VX-017, the blood type O version with similar target product profile to zimislece
Slide 11: Vertex to acquire Crinetics Pharmaceuticals for $10B
Vertex to acquire Crinetics Pharmaceuticals • Vertex to acquire Crinetics for $85/share in cash; unanimously approved by both Boards of Directors for $10B (~$8.8B net of cash) • Compelling fit with Vertex strategy: potential best-in- class commercialized and Phase 3 endocrinology assets with combine
Slide 12: R&D portfolio is broad, deep, and rapidly advancing
R&D portfolio is broad, deep, and rapidly advancing Select, Next Wave Phase 1 Phase (1)/2 Pivotal Submitted for Approved Research-stage Programs in Healthy Volunteers (in Patients) Development Accelerated Approval Improved conditioning Follow-on VX-407 Povetacicept Povetacicept CASGEVY – SCD & TDT m
Slide 13: $1B ALYFTREK H1:26 revenue milestone achieved
CF: Q2 global revenue growth of 11%, well balanced geographically $1B ALYFTREK H1:26 revenue milestone achieved • ALYFTREK rollout progressing well • Label expansions for ALY and TRI represent U.S. ~800 newly eligible CF patients highlights • Majority of ALY revenue from TRI switch patients • Very s
Slide 14: CASGEVY: Acceleration continues into 2026+ towards multi-$B potential
CASGEVY: Acceleration continues into 2026+ towards multi-$B potential Q2:26 CASGEVY revenue $76M • Received approval for ages 2 to <12 years in U.S. • Regulatory submissions for 5 to <12 years complete in KSA and the U.K. • Strong trends in Germany after reaching a historic access agreement for SCD
Slide 15: JOURNAVX launch continues to gain traction
JOURNAVX launch continues to gain traction JOURNAVX launch progress Strong clinical reception Ongoing access expansion Expanding hospital pathways Field activity momentum ~18K new ~260M ~1,400 ~300 field prescribers in covered lives hospitals & force Q2:26 >80% of covered ~130 health Increasing live
Slide 16: Renal: Building our fourth disease area pillar, starting with povetacicept in IgAN
Renal: Building our fourth disease area pillar, starting with povetacicept in IgAN Final stages of commercial launch preparations Providers Payers Patients ~4,000 nephrologists Commercial Patient programs critical treat ~80% Medicaid for chronic therapies, of U.S. IgAN patients Medicare especially b
Slide 17: Q2 2026 financial highlights
Q2 2026 financial highlights ($ in millions except where noted or per share data and percentages) Q2:25 FY:25 Q2:26 TRIKAFTA/KAFTRIO 2.55B 10.31B 2.50B ALYFTREK 157 838 574 Other CF product revenues 194 645 137 Total CF product revenues, net 2.90B 11.80B 3.21B CASGEVY 30 116 76 JOURNAVX 12 60 50 Tot
Slide 18: Raising full year 2026 revenue guidance
Raising full year 2026 revenue guidance Current FY 2026 Previous FY Commentary guidance 2026 guidance Full year revenue guidance includes expectations for continued growth in CF, Total Revenue $13.1 - $13.2B $12.95 - $13.1B as well as $500 million or more in revenue from non-CF products. Combined GA
Slide 19: Anticipated key milestones
Ma Anticipated key milestones Marketed CFTR modulators • Expand number of people treated: ultra-rare mutations, younger patients, additional geographies • Expand CF leadership and reach more patients around the globe by driving U.S. adoption and ongoing OUS launches in 6+ year olds ALYFTREK (CF) • C
Slide 20: Second Quarter 2026 Financial Results
FIRST QUARTER Second 2025Quarter 2026 FINANCIAL Financial Results RESULTS August 3, 2026 Presentation intended for the investment community ©2025 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated ©2025 Vertex Pharmaceuticals Incorporated
Slide 21: Appendix: GAAP to non-GAAP financial information
Appendix GAAP to non-GAAP financial information (in millions except per share amounts and percentages) Q2:25 FY:25 Q2:26 Combined R&D, AIPR&D and SG&A GAAP 1.41B 5.80B 1.60B Non-GAAP 1.24B 5.12B 1.43B Operating income GAAP 1.15B 4.17B 1.25B Non-GAAP 1.33B 5.26B 1.42B Operating Margin % GAAP 39% 35%